$3.06
3.03% yesterday
Nasdaq, Sep 04, 10:04 pm CET
ISIN
CA00430K4028
Symbol
GRCE

Acasti Pharma Inc. Class A Stock price

$3.06
+0.06 2.00% 1M
+0.31 11.27% 6M
-0.68 18.18% YTD
+0.56 22.40% 1Y
-1.86 37.80% 3Y
-6.63 68.41% 5Y
-145.74 97.94% 10Y
-84.73 96.51% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
+0.09 3.03%
ISIN
CA00430K4028
Symbol
GRCE
Industry

Key metrics

Basic
Market capitalization
$41.1m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 93.4
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
92.5%
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$0.0 | $439.6k
EBITDA
$-14.8m | $-17.9m
EBIT
$-14.8m | $-14.5m
Net Income
$-10.3m | -
Free Cash Flow
$-13.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-11.4% | -
EBIT
-11.0% | -
Net Income
9.9% | -
Free Cash Flow
-35.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -4,060.7%
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
-
Short interest
0.5%
Employees
-
Rev per Employee
-
Show more

Is Acasti Pharma Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Acasti Pharma Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Acasti Pharma Inc. Class A forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Acasti Pharma Inc. Class A forecast:

Buy
89%
Hold
11%

Financial data from Acasti Pharma Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.04 7.04
0% 0%
-
- Research and Development Expense 1.14 1.14
59% 59%
-
-15 -15
11% 11%
-
- Depreciation and Amortization 0.01 0.01
80% 80%
-
EBIT (Operating Income) EBIT -15 -15
11% 11%
-
Net Profit -10 -10
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Acasti Pharma Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Acasti Pharma Inc. Class A Stock News

Neutral
GlobeNewsWire
about 15 hours ago
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it will be featured as a presenting compa...
Neutral
GlobeNewsWire
9 days ago
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 PRINCETON, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics ...
Neutral
GlobeNewsWire
24 days ago
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)
More Acasti Pharma Inc. Class A News

Company Profile

Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Head office Canada
CEO Mr. Kohli
Founded 2002
Website www.gracetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today